In terms of commercializing its programs, Synthon Biopharmaceuticals chooses the optimum timing to partner each program. This might involve: taking a given product all the way to market or, alternatively, to partnering a technology or pipeline project at the appropriate stage or value inflection point.
Synthon Biopharmaceuticals develops next generation ADC products, both independently and in collaboration/ partnerships with biopharmaceutical companies that have suitable cancer antibody programs. We also consider in-licensing antibodies.
We welcome business opportunity proposals that may be complementary to our portfolio and fit with our strategy. For collaborative or (in/out) licensing opportunities or other partnering opportunities, please contact us.contact us